Key Data Files for this Active Pharmaceutical Ingredient:

Drug Master Files, 21 CFR, and other industry portals Patent/Exclusivity data file Drug Approval Drug Safety Freedom of Information Federal Register pages Pharma Companies Pharmacopeial Information Preferred API Supplier (Clients Only)

FDA Approval Activities for this Drug… Lovenox (enoxaparin sodium) Injection, Aventis NDA 20-164/S51 6/20/03 7/6/03 Lovenox (enoxaparin sodium) Injection, Aventis NDA 20-164/S50 7/1/03 7/8/03 Lovenox (enoxaparin sodium) Injection, 300 mg/3.0, Aventis Products NDA 20-164/S43 1/23/03 1/27/03 Lovenox (enoxaparin sodium) Injection, Aventis Products NDA 20-164/S40, S45 & S6 1/9/02 2/8/02 Lovenox (enoxaparin sodium) Injection Aventis Products NDA 20-164/S036 11/17/00 11/27/00 11/27/00 Lovenox (enoxaparin sodium) Injection Aventis Products NDA 20-164/S034 9/27/00 9/29/00 Lovenox (enoxaparin sodium) Injection Aventis Products NDA 20-164/S020 8/4/00 8/4/00 Lovenox (enoxaparin sodium) Injection Rhone-Poulenc Rorer NDA 20-164/S010 1/30/98 4/24/03 Lovenox (enoxaparin sodium) Injection Rhone-Poulenc Rorer NDA 20-164/S015 12/31/98 7/3/00 Lovenox (enoxaparin sodium) Injection, Subcutaneous (SC), or OTC: Rhone-Poulenc Rorer NDA 20-164 12/31/98 1/5/99 1/5/99 Lovenox Indications:(1) the inpatient treatment of acute deep vein thrombosis with and without pulmonary embolism, when administered in conjunction with warfarin sodium, and (2) the outpatients treatment of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium. Lovenox (enoxaparin sodium) Injection, Aventis Pharmaceuticals Lovenox (enoxaparin sodium) Injection, Aventis Pharmaceuticals Lovenox (enoxaparin sodium) Injection, Aventis Pharmaceuticals Lovenox (enoxaparin sodium, injection), Aventis Pharmaceuticals, Control Supplement   For the latest approval information, locate this drug using this index.